Ipsen will pay $450 million upfront to buy Kartos Therapeutics and its MDM2 protein-targeting drug candidate that it in-licensed from Amgen back in 2016.
June 29, 2026 07:15 AM EDT
DealsPharma
Ipsen to buy blood cancer company Kartos Therapeutics for $450M upfront
Ayisha Sharma
News Reporter
Ipsen’s $450M blood cancer drug; FDA selects first cohort for “pre-check” pilot program
Ipsen to buy Swiss biotech Memo Therapeutics in potential $800M deal
Fierce Pharma Asia—Historic solid tumor CAR-T nod; Inside Pfizer, Innovent’s $10B pact; More China deals
The planned acquisition of Kartos Therapeutics would hand Ipsen a late-stage asset for myelofibrosis. Elsewhere, Sobi hit a…
Ipsen buys Memo Therapeutics for €200M upfront, gaining kidney-transplant drug potravitug in its second deal this week.
The purchase hands Ipsen an experimental medicine in late-stage testing for a virus that often affects kidney transplant patients.
Ipsen's Dysport meets Phase 3 endpoints in migraine, Tarsus acquires iRenix for $75M+, Alchemab raises $34M, and more.
Pathos AI is raising up to $300M at a ~$3B valuation and inks deals for Alphamab's TROP2/HER3 ADC ($125M upfront) and…
Cardiology biotech Kardigan prices its Nasdaq IPO at $16, the top of range, raising $400M ahead of a Thursday debut.
